Suppr超能文献

监测活检在婴儿心脏移植受者中的应用价值。

Utility of surveillance biopsies in infant heart transplant recipients.

作者信息

Balzer D T, Moorhead S, Saffitz J E, Huddleston C B, Spray T L, Canter C E

机构信息

Division of Pediatric Cardiology, Washington University School of Medicine, St. Louis Children's Hospital, Mo 63110, USA.

出版信息

J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 1):1095-101.

PMID:8719456
Abstract

BACKGROUND

Endomyocardial biopsy remains the primary means of rejection surveillance after orthotopic heart transplantation in adults. Perpetual surveillance endomyocardial biopsy has been questioned, however, because of low yield beyond the early posttransplantation period. This issue has not been adequately studied in the pediatric population. The objectives of this study were to define the rate of rejection in infants undergoing orthotopic heart transplantation, correlate rejection with signs and symptoms, and evaluate the utility of surveillance endomyocardial biopsy.

METHODS

Records of all patients 24 months of age or younger undergoing orthotopic heart transplantation were reviewed; 38 patients underwent 42 transplantation; 256 endomyocardial biopsies were performed for surveillance, cardiac symptoms, noncardiac symptoms, or lowered immunosuppression.

RESULTS

There were 22 rejection episodes International Society for Heart and Lung transplantation grade 1B or higher, half of which occurred in neonates 30 days of age or younger. Linearized rejection rates and actuarial freedom from rejection were not different between neonates and older infants. Linearized rejection rates reached a plateau 3 months after orthotopic heart transplantation of 0.07 episodes/100 patient days. No positive surveillance endomyocardial biopsies were obtained beyond 6 months after orthotopic heart transplantation. The probability of a positive biopsy (International Society for Heart and Lung Transplantation grade 1B or higher) was 20% or more for any other indication (odds ratios for rejection were 12.9 for cardiac symptoms, 3.3 for noncardiac symptoms, and 10.8 for lowered immunosuppression as determined by logistic regression more than 6 months after orthotopic heart transplantation).

CONCLUSIONS

Rejection rates are not different between neonatal and older infants, and endomyocardial biopsies done solely for surveillance beyond 6 months after orthotopic heart transplantation rarely yield positive results.

摘要

背景

心内膜心肌活检仍然是成人原位心脏移植后排斥反应监测的主要手段。然而,由于移植后早期以外的活检阳性率较低,持续监测的心内膜心肌活检受到了质疑。这个问题在儿科人群中尚未得到充分研究。本研究的目的是确定接受原位心脏移植的婴儿的排斥反应发生率,将排斥反应与体征和症状相关联,并评估监测心内膜心肌活检的效用。

方法

回顾了所有24个月及以下接受原位心脏移植患者的记录;38例患者接受了42次移植;进行了256次心内膜心肌活检以进行监测、心脏症状、非心脏症状或免疫抑制降低的情况评估。

结果

有22次国际心肺移植学会1B级或更高等级的排斥反应发作,其中一半发生在30天及以下的新生儿中。新生儿和较大婴儿之间的线性化排斥反应率和无排斥反应的精算自由度没有差异。原位心脏移植后3个月,线性化排斥反应率达到平稳状态,为0.07次发作/100患者日。原位心脏移植后6个月以上未获得阳性监测心内膜心肌活检结果。对于任何其他指征,活检阳性(国际心肺移植学会1B级或更高等级)的概率为20%或更高(原位心脏移植后6个月以上通过逻辑回归确定,心脏症状的排斥反应优势比为12.9,非心脏症状为3.3,免疫抑制降低为10.8)。

结论

新生儿和较大婴儿的排斥反应率没有差异,原位心脏移植后6个月以上仅为监测而进行的心内膜心肌活检很少产生阳性结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验